The introduction of immune checkpoint inhibitors (ICIs) for advanced and metastatic forms of non-melanoma skin cancers (NMSC) has changed management, adding both opportunities and challenges. In this activity, nurses will gain a practical understanding of the role of ICIs in NMSC management, including how they work, how to communicate safety and efficacy expectations to patients, safe administration and handling practices, how to recognize and characterize immune-related adverse events (irAEs), including why irAEs happen, and how to differentiate life-threatening irAEs from common side effects.
Upon completion of this activity, participants should be better able to:
Nurse Practitioner, Center for Melanoma/Cutaneous Oncology
Mass General Cancer Center
Boston, MA
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
